Hlaváč et al reported that patients with CYP2W1 expression responded better to a NACT regimen based on 5‐fluorouracil, adriamycin, cyclophosphamide or 5 fluorouracil, epirubicin, cyclophosphamide, and taxanes, which suggest that these commonly used breast cancer chemotherapy agents may be metabolised by CYP2W1 [13]. This evidence concerns the gene CYP2W1 and breast carcinoma.